Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

{"title":"Collaborative innovations in diabetes self-care for individuals with type 2 diabetes and schizophrenia: A Participatory Design study developing a diagnosis-specific educational manual","authors":"Tanja Juhl Mikkelsen ,&nbsp;Dorte Moeller Jensen ,&nbsp;Elsebeth Stenager ,&nbsp;Mette Juel Rothmann","doi":"10.1016/j.dsx.2025.103220","DOIUrl":"10.1016/j.dsx.2025.103220","url":null,"abstract":"<div><h3>Background and aims</h3><div>Individuals with schizophrenia are at high risk of developing type 2 diabetes. This study aimed to develop a tailored solution to address their complex diabetes care needs, based on insights from patients and healthcare professionals, to enhance self-care.</div></div><div><h3>Methods</h3><div>Using a Participatory Design approach, we conducted three workshops and an evaluation, which included focus groups, interviews, and written feedback. Patients, healthcare professionals, and stakeholders actively participated in all stages of the process between May 2022 and December 2023. Iterative processes ensured comprehensive input in idea generation and concept development. Data analysis followed the steps of planning, acting, observing, and reflecting. The study is reported using SRQR framework.</div></div><div><h3>Results</h3><div>Participants highlighted challenges such as navigating a fragmented healthcare system, undertreatment, and stigma. In response, a tailored educational manual for voluntary mentors was developed. This two-day training program equips mentors to support individuals with type 2 diabetes and schizophrenia, fostering collaboration and bridging the gap between psychiatric and somatic care.</div></div><div><h3>Conclusions</h3><div>A co-designed approach may enhance diabetes self-care and improve coordination between healthcare sectors.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103220"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic variation in targets of antihyperglycemic drugs and inflammatory bowel disease’ risk: A mendelian randomization study","authors":"Jiaxi Zhao ,&nbsp;Rong Chen ,&nbsp;Mengqi Luo ,&nbsp;Quanjing Zhu ,&nbsp;Qian Zhao","doi":"10.1016/j.dsx.2025.103204","DOIUrl":"10.1016/j.dsx.2025.103204","url":null,"abstract":"<div><h3>Aim</h3><div>Antihyperglycemic drugs have potential therapeutic benefits for inflammatory bowel disease (IBD). We aimed to investigate the association between genetic variations in gene-targeted antihyperglycemic drugs and the risk of IBD.</div></div><div><h3>Methods</h3><div>Summary statistics for HbA1c data were from the UK Biobank including 344,182 participants. Statistics of IBD were obtained from UK Inflammatory Bowel Disease Genetics. Two Mendelian randomization methods were employed to derive the main findings.</div></div><div><h3>Results</h3><div>In the SMR analysis, increased expression of genetic variations in SGLT2 inhibitor targets (gene: SLC5A2) was linked to a higher risk of CD (OR: 1.97, <em>P</em> = 0.048). Genetic variation in brain cerebellum tissue of sulfonylurea targets (gene: ABCC8) expression was positively associated with IBD (OR = 1.11, <em>P</em> = 0.000). The genetic variation in the GLP-1RA targets (gene: GLP1R) expression was positively correlated with IBD (OR: 1.45, <em>P</em> = 0.039). The IVW-MR analysis suggested reduced IBD and CD risk with expression of increased genetic variation in the thiazolidinediones targets (gene: PPARG).</div></div><div><h3>Conclusion</h3><div>Genetic variations in SGLT2 inhibitor targets might be associated with an increased risk of CD. The ABCC8 gene might be linked to IBD, CD, and UC. There might be a positive correlation between genetic variation in the GLP-1RA targets expression and IBD occurrence.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103204"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143519111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5–15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials","authors":"Akriti Singh ,&nbsp;Awadhesh Kumar Singh ,&nbsp;Ritu Singh ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2025.103212","DOIUrl":"10.1016/j.dsx.2025.103212","url":null,"abstract":"<div><h3>Background and aims</h3><div>Both semaglutide 2.4 mg and tirzepatide have been recently approved for chronic use in obesity. There is a lack of literature comparing the efficacy and safety of both these agents in people with obesity/overweight with or without type 2 diabetes (T2D). We systematically reviewed Phase 3 randomized controlled trials (RCTs) conducted with two agents to synthesize the comparative efficacy and safety outcomes.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed electronic databases until December 15, 2024, using selected keywords and Boolean “AND.” Subsequently, we compared the most closely matched trials conducted with semaglutide 2.4 mg and tirzepatide through an adjusted (if baseline imbalance in treatment outcome modifiers present) or unadjusted (in the absence of baseline imbalance) indirect treatment comparison method.</div></div><div><h3>Results</h3><div>We identified one trial each of semaglutide 2.4 mg (STEP-1) and tirzepatide 5, 10, and 15 mg (SURMOUNT-1) in obese or overweight people without T2D and one trial each of semaglutide 2.4 mg (STEP-2) and tirzepatide 10 and 15 mg (SURMOUNT-2) in overweight people with T2D that were almost entirely comparable concerning baseline outcome modifier characteristics. Our unadjusted analysis without individual patients' data found relatively higher (4 and 5.4 % additional) weight loss, HbA1c (−0.4 % additional) reduction, and fewer gastrointestinal side effects (GI S/E) with tirzepatide 10 and 15 mg, respectively, than with semaglutide 2.4 mg, in the intention-to-treat analysis.</div></div><div><h3>Conclusion</h3><div>Tirzepatide 10 and 15 mg are more effective and have fewer GI S/E than semaglutide 2.4 mg. A well-powered head-to-head RCT is currently needed to confirm these findings.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103212"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143619681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal serum folate status during early pregnancy: Sex-specific association with neonatal adiposity","authors":"Nishanthi Periyathambi ,&nbsp;Nithya Sukumar ,&nbsp;Yonas Ghebremichael-Weldeselassie ,&nbsp;Antonysunil Adaikalakoteswari ,&nbsp;Chittaranjan Yajnik ,&nbsp;Caroline Fall ,&nbsp;Ponnusamy Saravanan","doi":"10.1016/j.dsx.2025.103222","DOIUrl":"10.1016/j.dsx.2025.103222","url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>Early pregnancy folate has been associated with GDM and possible adiposity in the newborn. The present study examined associations between maternal early pregnancy folate levels and sex-specific neonatal anthropometry. We further explored possible mediation by maternal glycemia on the association between folate and neonatal adiposity.</div></div><div><h3>Methods</h3><div>Sub-group data (<em>n</em> = 511) from a UK multi-ethnic early pregnancy longitudinal study (micronutrients in Pregnancy as a Risk factor for gestational Diabetes and Effects on mother and baby; PRiDE) was used. Maternal serum folate was assessed during early pregnancy (Mean ± SD = 12.5 ± 1.6 gestational weeks) and infant anthropometry including skinfold thickness (SFT) and mid-upper arm circumference (MUAC) at birth. Multiple linear regression was performed to analyse the relationship between maternal folate and infant adiposity indices. Interaction analysis was used to identify maternal glucose mediation of this relationship.</div></div><div><h3>Results</h3><div>Excess folate levels (≥45 nmol/l) were found in 40.3 % pregnant women (<em>n</em> = 206). Early pregnancy folate (1 SD unit) was positively associated with male newborn triceps SFT (std β = 0.17 (95 % CI: 0.06, 0.29; <em>p &lt;</em> 0.05)) after adjusting for key maternal and infant confounders in multiple comparisons using Benjamini-Hochberg procedure. However, no associations were seen in female newborns. No influence of maternal fasting (FPG) and 2-h plasma glucose (2 h-PG) were detected on the association between folate and newborn anthropometry.</div></div><div><h3>Conclusion</h3><div>Our findings suggest a potential sex-specific influence of maternal folate on infant anthropometric indices. The association between early pregnancy folate on newborn adiposity was not mediated by maternal FPG and/or 2 h-PG at 24–28 weeks.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103222"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Frequency Rhythmic Electrical Modulated System (FREMS) in the treatment of diabetic neuropathy: A systematic review and meta-analysis of randomized controlled trials","authors":"Alireza Azarboo ,&nbsp;Parisa Fallahtafti ,&nbsp;Amin Javidan ,&nbsp;Negar Zareshahi ,&nbsp;Hossein Souri Giglou ,&nbsp;Shabboo Moayyed ,&nbsp;Amirhossein Ghaseminejad-Raeini ,&nbsp;Mahboobeh Hemmatabadi","doi":"10.1016/j.dsx.2025.103223","DOIUrl":"10.1016/j.dsx.2025.103223","url":null,"abstract":"<div><h3>Background</h3><div>Painful diabetic peripheral neuropathy (DPN) is a debilitating complication of diabetes with limited treatment options. Frequency Rhythmic Electrical Modulated System (FREMS), a non-invasive electrotherapy, has shown promise in symptom management.</div></div><div><h3>Methods</h3><div>Databases, including PubMed, Scopus, and Embase were searched until October 2024. Randomized controlled trials (RCTs) involving adults with DPN comparing FREMS with control were included. Data on Visual Analog Scale (VAS) scores and nerve conduction were extracted. Standardized mean differences (SMDs) with 95 % confidence intervals (CIs) were pooled using random-effects models. Risk of bias was assessed using RoB 2. Heterogeneity was quantified via I² statistics, with sensitivity analyses and publication bias evaluation.</div></div><div><h3>Results</h3><div>Five RCTs (333 participants) were included. Meta-analysis indicated that FREMS significantly reduced daytime VAS pain scores post-treatment (SMD -0.56, 95 % CI -0.82 to −0.29, I² = 4 %) and at follow-up (SMD -0.47, 95 % CI -0.73 to −0.21, I² = 0 %). Night-time VAS pain scores also improved post-treatment (SMD -0.54, 95 % CI -0.80 to −0.27, I² = 44 %) and at follow-up (SMD -0.38, 95 % CI -0.65 to −0.12, I² = 1 %). FREMS improved motor nerve conduction but showed no effect on sensory conduction or microvascular blood flow.</div></div><div><h3>Conclusion</h3><div>FREMS effectively reduces DPN pain with sustained benefits and a favorable safety profile. Further research should standardize treatment protocols and assess long-term outcomes for clinical integration.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103223"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor regarding “The impact of food-based dietary strategies on achieving type 2 diabetes remission: A systematic review”","authors":"Irfat Islam Eva ,&nbsp;Priyadarshini Deb ,&nbsp;Muhammad Ali Muzammil","doi":"10.1016/j.dsx.2025.103188","DOIUrl":"10.1016/j.dsx.2025.103188","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103188"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the Letter to the Editor regarding “The impact of food-based dietary strategies on achieving type 2 diabetes remission: A systematic review”","authors":"Hadis Mozaffari ,&nbsp;Annalijn I. Conklin","doi":"10.1016/j.dsx.2025.103189","DOIUrl":"10.1016/j.dsx.2025.103189","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103189"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes care in Gaza: A call to action for providing healthcare amid conflict","authors":"Sumarno Adi Subrata","doi":"10.1016/j.dsx.2025.103210","DOIUrl":"10.1016/j.dsx.2025.103210","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103210"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Possible sarcopenia, sarcopenic obesity phenotypes and their association with diabetes: Evidence from LASI wave-1 (2017-18)","authors":"Inderdeep Kaur ,&nbsp;Shromona Das ,&nbsp;Shivangi Chandel ,&nbsp;Shivani Chandel","doi":"10.1016/j.dsx.2025.103185","DOIUrl":"10.1016/j.dsx.2025.103185","url":null,"abstract":"<div><h3>Aims</h3><div>To assess the prevalence of possible sarcopenia and sarcopenic obesity phenotypes and investigate their association with self-reported diabetes among community-dwelling individuals aged 45 or above.</div></div><div><h3>Methods</h3><div>Utilizing data from 62,899 individuals in LASI wave-1 (2017-18), the assessment of possible sarcopenia was done on two critical parameters: muscle (handgrip) strength and physical performance (gait speed), following the 2019 guidelines from the Asian working group on sarcopenia (AWGS). BMI, WC, WHR, and WHtR defined sarcopenic obesity phenotypes. Binary logistic regression analysis explored the association of possible sarcopenia and sarcopenic obesity phenotypes with self-reported diabetes.</div></div><div><h3>Results</h3><div>The prevalence of possible sarcopenia and sarcopenic obesity defined by BMI was found to be 44.4 % and 10.6 %, respectively. Individuals with possible sarcopenia exhibited a 1.18 times higher likelihood of developing self-reported diabetes (p &lt; 0.001), while those with sarcopenic obesity by BMI had significantly elevated odds (1.94, 95 % CI 1.81–2, p &lt; 0.001) for self-reported diabetes.</div></div><div><h3>Conclusions</h3><div>Sarcopenia and sarcopenic obesity phenotypes may increase the risk of developing diabetes as we age. Therefore, it is imperative to formulate targeted preventive and therapeutic strategies to combat sarcopenia and diabetes among the aging population.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103185"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of type 1 diabetes mellitus on mortality rate and outcome of hospitalized patients with myocardial infarction","authors":"Volker H. Schmitt ,&nbsp;Lukas Hobohm ,&nbsp;Omar Hahad ,&nbsp;Visvakanth Sivanathan ,&nbsp;Frank P. Schmidt ,&nbsp;Thomas Münzel ,&nbsp;Philipp Lurz ,&nbsp;Tommaso Gori ,&nbsp;Karsten Keller","doi":"10.1016/j.dsx.2025.103201","DOIUrl":"10.1016/j.dsx.2025.103201","url":null,"abstract":"<div><h3>Introduction</h3><div>Type 1 diabetes mellitus (T1D) is associated with an increased cardiovascular risk. We aimed to investigate the influence of T1D on myocardial infarction (MI) patients’ mortality.</div></div><div><h3>Materials and methods</h3><div>The German nationwide inpatient sample 2005–2016 was used for statistical analysis. Hospitalized MI patients were stratified for T1D and impact of T1D on in-hospital outcomes was investigated.</div></div><div><h3>Results</h3><div>In total, 3,307,703 hospitalizations of MI patients (37.6 % females, 56.8 % aged ≥70 years) were counted in Germany 2005–2016 and included in this analysis. In 18,625 (0.6 %) of the cases additionally T1D was coded. Overall, 410,737 (12.4 %) in-hospital deaths occurred within the investigation period. MI patients with T1D were younger (64.0 [IQR 52.0–75.0] vs. 73.0 [62.0–81.0] years, P &lt; 0.001), more often female (38.7 % vs. 37.6 %, P &lt; 0.001) and obese (13.2 % vs. 9.3 %, P &lt; 0.001). Comorbidities like peripheral arterial (14.2 % vs. 6.4 %, P &lt; 0.001) and kidney disease (38.5 % vs. 27.2 %, P &lt; 0.001) were more prevalent in MI patients with T1D. T1D was an independent risk factor for in-hospital death (OR 1.23 [95%CI 1.18–1.29], P &lt; 0.001), recurrent MI (OR 1.56 [95%CI 1.35–1.80], P &lt; 0.001), and stroke (OR 1.75 [95%CI 1.63–1.88], P &lt; 0.001). While percutaneous coronary intervention (PCI, 37.8 % vs. 42.0 %, P &lt; 0.001) was less often, coronary artery bypass grafting (CABG, 7.4 % vs. 4.6 %, P &lt; 0.001) was more often performed in MI patients with T1D, confirmed by regression analysis (PCI: OR 0.66 [95%CI 0.64–0.68], P &lt; 0.001; CABG: OR 1.54 [95%CI 1.45–1.63], P &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>T1D represents an important and independent risk factor for mortality in MI patients. The results emphasize the high vulnerability of T1D patients who suffer from MI.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103201"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}